Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours by de Jonge, M J A et al.
Phase I and pharmacokinetic study of XR11576, an oral
topoisomerase I and II inhibitor, administered on days 1–5 of
a 3-weekly cycle in patients with advanced solid tumours
MJA de Jonge*,1, S Kaye
2, J Verweij
1, C Brock
2, S Reade
2, M Scurr
2, L van Doorn
1, C Verheij
1, W Loos
1,
C Brindley
3, P Mistry
4, M Cooper
5 and I Judson
2
1Department of Medical Oncology, Erasmus Medical Center/Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The
Netherlands;
2Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK;
3Quintiles Limited, Research Avenue South, Heriot Watt University, Research
Park, Riccarton, Edinburgh, EH14 4AP, UK;
4Xenova Limited, 957 Buckingham Ave, Slough, SL1 4NL, UK;
5Millennium Pharmaceuticals Inc, 350
Massachusetts Avenue, Cambridge, MA 02139, USA
XR11576 is an oral topoisomerase I and II inhibitor. The objectives of this phase I study were to assess the dose-limiting toxicities
(DLTs), to determine the maximum tolerated dose (MTD) and to describe the pharmacokinetics (PKs) of XR11576 when
administered orally on days 1–5 every 3 weeks to patients with advanced solid tumours. Patients were treated with escalating doses
of XR11576 at doses ranging from 30 to 180mgday
 1. For PK analysis, plasma sampling was performed during the first and second
courses of treatment and XR11576 concentrations were assayed using a validated high-performance liquid chromatographic assay
with mass spectrometric detection. In all, 21 patients received a total of 47 courses. The MTD was reached at 180mgday
 1, with
diarrhoea and fatigue as DLT. Nausea and vomiting, although not qualifying for DLT, was ubiquitous. Only in combination with an
extensive prophylactic antiemetic regimen consisting of a combination of both dexamethasone and a 5HT3 antagonist was treatment
with XR11576 at 120mgday
 1 tolerable. The systemic exposure of XR11576 increased more than proportionally with increasing
dose, with a large interpatient variability. No objective responses were seen; four patients experienced stable disease for periods of
12–30 weeks. In this study, the DLTs of XR11576 were diarrhoea and fatigue. The recommended dose for phase II studies of
XR11576 is 120mg administered orally, on days 1–5 every 21 days. Alternative regimens are currently being explored.
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DNA topoisomerases are essential nuclear enzymes involved in
multiple nuclear functions such as chromosomal recombination,
DNA repair, transcription and chromatin assembly (Eng
et al, 1988; Hsiang et al, 1989). Topoisomerase I and II inhibitors
are of great clinical interest because of their important antitumour
activity in a broad spectrum of tumour types (Rothenberg, 1997).
The expression of topoisomerase I and IIb does not vary
significantly during the cell cycle, whereas topoisomerase
IIa expression increases during the S phase and reaches a peak
at G2/M phase (Heck et al, 1988). It has been shown in preclinical
studies that crossresistance between topoisomerase I and II
inhibitors is unusual in resistant cell lines (Ferguson et al, 1988).
Alterations in the regulation of one topoisomerase are often
compensated by alterations in the other (Lefevre et al, 1991). Joint
inhibitors of topoisomerase I and II appear to combine the
properties of the individual specific inhibitors but act across
the cell cycle, and so target a larger population of cells in
any asynchronous population, resulting in greater antitumour
activity. Several of these ‘dual inhibitors’ have been identified,
including intoplicin, saintopin, XR5000 and F11782 (Newman et al,
1999; Twelves et al, 1999; Etievant et al, 2000; Denny and Baguley,
2003).
4-methoxy-benzo[a]phenazine-11-carboxylic acid (2-dimethu-
lamino-1-R-methyl-ethyl)-amide (XR11576) is a novel substituted
benzo[a]phenazine-11-carboxamide that targets both topoisome-
rase I and II (Figure 1) (Jobson et al, 2002; Wang et al, 2002).
In vitro, XR11576 exerted antitumour activity against a variety
of murine and human tumour cell lines, including rapidly
proliferating murine leukaemias and human colon, breast, ovarian
and lung carcinoma cell lines. In vivo, XR11576 was highly active
against human colon and small-cell lung cancer xenografts (Mistry
et al, 2002; Lewis et al, 2003). XR11576 was also active against
multidrug-resistant cells overexpressing P-gp or MRP, or against
cells with downregulation of topoisomerase II levels (Di Nicolan-
tonio et al, 2002). On giving XR11576 orally to rodents and dogs,
its antitumour activity was preserved.
In animals, XR11576 predominantly induced bone marrow and
gastrointestinal toxicity. In addition, when i.v. doses were
repeatedly administered to dogs, myocarditis and nephritis were
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lobserved. However, these toxicities were not observed in studies of
repeated oral dosing. Furthermore, no cardiac toxicity was
detected in a cardiovascular safety study (data on file, FPD
1055). The maximum tolerated doses (MTDs) in a 14-day oral
administration schedule in rats and 8/9-day oral administration
schedule in dogs were 150 and 200mgm
 2, respectively. The oral
route of administration was chosen because the i.v. route induced
unacceptable vein irritation and because XR11576 had proven
activity when given orally, which would enable a more convenient
method of prolonged drug administration and create the
opportunity for cost-effective outpatient therapy.
The pharmacokinetics (PKs) of XR11576 have been studied in
several animal species. After single intravenous administration,
XR11576 rapidly distributed from plasma into the tissues, resulting
in a large volume of distribution. After both i.v. and oral
administration to mice and rats, high tissue levels of XR11576
relative to plasma were observed, with the highest and most
prolonged drug levels in tumour tissue. The oral availabilities of
XR11576 in mice and rats were 72725 and 54732%, respectively.
In mice, food reduced the bioavailability. After single oral
administration to dogs, the systemic exposure increased more
than dose-proportionally. The unchanged drug was the major
component in plasma. However, there was evidence of hepatic
metabolism to at least one major metabolite. Plasma half-life
varied between 1 and 9h. Repeated daily oral doses in dogs did
result in a reduction in the systemic exposure of approximately
60%, which might be related to the observed gastrointestinal
toxicity. The main route of elimination of XR11576 is likely to be
hepatic metabolism.
The purposes of the present phase I study were to determine the
MTD of XR11576 administered orally on days 1–5 every 21 days,
to establish the dose-limiting and other toxic effects, to describe
the PK of XR11576, to document any antitumour effects and to
establish a dose suitable for further phase II evaluation of activity
of the compound.
PATIENTS AND METHODS
Patient selection
Patients with a cytologically or histologically confirmed diagnosis
of a malignant solid tumour refractory to standard forms of
therapy were eligible for this study, provided that they met the
following criteria: age between 18 and 75 years; WHO performance
status p1; estimated life expectancy X3 months; no previous
anticancer therapy for at least 4 weeks; no major fluid effusions; no
significant gastric or small intestine disease that might influence
the absorption of the drug; and adequate haematopoietic
(haemoglobin X5.2mmoll
 1, absolute peripheral granulocyte
count X2.0 10
9l
 1 and platelet count X100 10
9l
 1), hepatic
(bilirubinpthe upper normal limit, and serum aspartate amino-
transferase and alanine aminotransferasep3.0 times the upper
normal limit) and renal (serum creatinine concentrationpthe
upper normal limit) functions. Patients with symptomatic brain or
leptomeningeal metastases were excluded. Patients had to be able
to swallow size 1 capsules. All patients gave written informed
consent before study entry. The study was approved by the
Institutions’ Medical Ethic Committees.
Treatment and dose escalation
XR11576 was supplied by Fulcrum Pharma Developments Ltd
(Hemel Hempstaed, UK) as size 1 gelatin capsules comprising 5.0,
20.0, 60.0 and 120.0mg of active drug and dibasic calcium
phosphate anhydrous. The capsules were stored at room
temperature (251C or below). Capsules were taken once a day,
with a glass of water after an overnight fasting of at least 2h before
breakfast. The daily dose of XR11576 was provided in separate
boxes, each of which was clearly identifiable by the patient.
Patients were instructed to record their daily amount of capsules
taken, the time of administration and the timing in relation to
breakfast. Compliance with the scheduled treatment was assessed
at the end of each course, by counting the used and returned
capsules of XR11576 in relation to the record kept by the patient
for the given cycle. With the exception of the first and second
courses, during which patients were hospitalised for PK sampling,
patients were treated on an outpatient basis.
The starting dose of XR11576 was 30mgday
 1, one out of three
of the no observed adverse effect level and one out of 10 of the
MTD in rat and dog. Since for most anticancer agents dosing
according to body surface area does not reduce the interpatient
variability in PKs, it was decided to use absolute doses of XR11576
and study the relation between oral clearance of XR11576 and the
body surface area (Ratain, 1998). The total dose prescribed was
rounded to the nearest 5mg. At least three patients were entered at
each dose level. Dose escalations between cohorts were based on
the prior dose level’s toxicity and pharmacological data, allowing a
dose escalation up to 100% (which was determined by the worst
significant toxicity). Once Xgrade 2 toxicity was observed in one
patient, further dose escalation did not exceed 50%. The stopping
dose was defined as the dose level that induced dose-limiting
toxicity (DLT) during course 1 in X2/3 or X2/6 patients. Dose-
limiting toxicities were defined as grade 4 granulocytopenia for 7
or more days, febrile neutropenia, platelets o25.0 10
9l
 1 and/or
nonhaematological toxicity Xgrade 3. Nausea and vomiting
subsequently responding to antiemetic therapy were excluded
from DLT. Treatment with XR11576 was resumed when the ANC
count had recovered to X2.0 10
9l
 1, the platelet count was
X100 10
9l
 1 and nonhaematological toxicity had recovered to
their baseline values. If a patient encountered DLT, the dose of
XR11576 was decreased by one dose level at re-treatment. In case
the toxicity had not recovered within 2 weeks of the planned re-
treatment time, the patient would go off-study. At the dose
recommended for further studies, the number of patients treated
could be expanded to 12. Toxicities were evaluated according to
the National Cancer Institute Common Toxicity Criteria, version
2.0 (ctep.info.nih.gov/reporting/index.html).
Treatment assessment
Before treatment, a complete medical history was recorded and a
physical examination performed. A complete blood count (CBC)
including white blood cell differential and serum biochemistry,
which involved sodium, potassium, calcium, urea, creatinine, uric
acid, total protein, albumin, total bilirubin, alkaline phosphatase,
g-glutamyl transferase, aspartate aminotransferase, alanine amino-
transferase, lactate dehydrogenase and glucose, were performed, as
were urinalysis, pregnancy test, relevant tumour markers, electro-
cardiogram and a chest X-ray. The electrocardiogram was also
performed 2 and 24h after the first drug administration in the first
and second cycles. Weekly evaluations included history, physical
examination, toxicity assessment according to the CTC criteria
version 2.0, and serum chemistries. Complete blood count was
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Figure 1 Chemical structure of XR11576.
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ldetermined twice weekly. Tumour evaluation was performed after
every two courses according to the Response Evaluation Criteria in
Solid Tumours (RECIST) (Therasse et al, 2000). Patients were
taken off protocol at the onset of disease progression.
Sample collection and drug analysis
For PK analysis, 58 blood samples (B5ml each) were obtained
from an indwelling intravenous cannula and collected in vials
containing lithium heparin as anticoagulant. The samples were
taken immediately before dosing, 30min and 1, 1.5, 2, 3, 4, 6, 8 and
10h after administration of the drug on days 1 and 4 (or 5) of the
first and second courses. Additional samples were taken im-
mediately prior to dosing on days 2, 3, 4 and 5, and 24, 48, 72, 144
and 312h after the dose administration on day 5, both in the first
and second cycles. From the third cycle onwards, PK samples were
taken prior to dosing on day 5 to measure the potential
accumulation of XR11576.
All samples were centrifuged immediately after sampling at
3000r.p.m. for 10min at 41C and the plasma was stored at  201C
or lower in polypropylene tubes in the dark until analysis. A total
of four urine samples were also collected over a 24-h period; 0–4,
4–8, 8–12 and 12–24h post-dosing on day 1 of the first cycle only.
Of the total amount collected, a measured quantity of 10ml was
drawn off and stored at  801C until analysis. Concentrations of
XR11576 in plasma were determined according to a validated
liquid chromatography-mass spectrometry detection method with
liquid–liquid extraction at the Drug Metabolism and Pharmaco-
kinetics Department of Quintiles Limited (Internal Report at
Quintiles). The lower limit of quantitation was 5ngml
 1.
PK data analysis
The apparent terminal half-life (T1/2(z)) of XR11576 was calculated
as ln2/k, where k is the terminal elimination rate constant
(expressed in h
 1). The peak plasma concentrations (Cmax) and the
time to peak plasma concentration (Tmax) were determined from
the experimental values. The areas under the plasma concentra-
tion–time curve (AUC) of XR11576 were estimated using the
experimental values (trapezoidal rule) with extrapolation to
infinity (AUC0–N) using the apparent terminal rate constant,
defined as the slope of the final three to four data points of the log-
linear concentration–time plot. The total body clearance (CL) was
calculated as the ratio between the administered dose and the
AUC0–N. The extent of accumulation (R0) in plasma was
calculated from AUC0–24h (days 4 or 5)/AUC0–24h (day 1). The
fraction of the administered dose (Fe) excreted in urine and the
cumulative amount of XR11576 excreted in urine (Ae) was
determined. PK data analysis was carried out using a noncompart-
mental analysis approach with the aid of WinNonlin Version
Pron4.0.1 (Pharsight, Cary NC 27511).
Statistical analysis A nonlinear power model was used to assess
dose proportionality separately for each day during cycles 1 and 2.
Statistical analyses were performed using SAS version 8.1.
RESULTS
Between January 2002 and April 2003, 22 patients, whose main
characteristics are listed in Table 1, were enrolled onto the study at
two centres. All patients were eligible. One patient, entered at the
120mgday
 1 dose level, did not receive any medication due to
deterioration of his condition prior to study start. The majority of
the patients were either asymptomatic or had only mild symptoms
at study entry. Patients were pretreated with a median of two prior
chemotherapy regimens (range 1–6). The total number of
assessable courses was 47. The median number of courses per
patient was 2 (range 1–10). Dose levels studied were 30, 60, 120,
180 and 150mgday
 1 XR11576 administered orally on days 1–5,
with courses repeated once every 21 days. Toxicity did not
necessitate dose reductions. However, three patients went off study
because of the toxicity experienced at the 120 (1 patient) and
180mgday
 1 (2 patients) dose levels. In the absence of DLT, the
dose of XR11576 was escalated from 30 to 180mgday
 1. Since all
previously entered patients on the 120mgday
 1 dose level had
experienced grade 2 nausea/vomiting during treatment, which
could not be ameliorated by the use of prokinetic antiemetics, it
was decided to introduce the use of prophylactic 5HT3 antagonists
at the 180mgday
 1 dose level. At the 180mgday
 1 dose level, DLT
was encountered in two of three patients. One of the patients
experienced fatigue grade 3 in the first treatment course. The
second patient considered to have DLT experienced in her first
cycle grade 2 diarrhoea, vomiting and fatigue. For a coincident
upper airway infection, she was treated with antibiotics. In her
second cycle, she experienced diarrhoea grade 4 in combination
with nausea grade 1, fatigue grade 2, hypotension grade 3 and
electrolyte disturbances grade 3. Although the diarrhoea might
have been aggravated by the previous use of antibiotics, the event
was considered study drug related. In spite of the fact that the DLT
in this second patient was observed in the second cycle, it was
decided that the dose of 180mgday
 1 was not feasible. At this
point, the previous dose level of 120mgday
 1 was expanded. The
first two additional patients did not encounter DLT. However,
despite the prophylactic use of 5HT3 antagonists, they experienced
nausea/vomiting grade 2. Therefore, the next three patients at the
120mgday
 1 dose level received a combination of 5HT3 antago-
nists and dexamethasone prophylactically, rendering the level of
nausea and vomiting acceptable. One of the additional patients at
this dose level experienced diarrhoea grade 3. It was subsequently
decided to explore an intermediate dose level: 150mgday
 1 in
three patients. At this dose 1, patient experienced grade 3
diarrhoea accompanied by neutropenia grade 4, nausea/vomiting
grade 2 and fatigue grade 2, considered to be DLT. All three
patients showed nausea/vomiting grade 2 despite the use of
prophylactic 5HT3 antagonists and dexamethasone prior to and
during the 5 days of treatment administration, and despite the use
Table 1 Patient characteristics
Characteristic No. of patients
No. entered 22
No. assessable 21
Age (years)
Median 56
Range 35–70
Sex
Female 13
Male 8
Performance status
WHO 0 3
WHO 1 18
Tumour type
Colorectal 6
Cervical 4
Melanoma 4
SCLC 2
Miscellaneous 5
Previous treatment
Chemotherapy 9
Chemotherapy and radiation 11
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lof a tapering dose of dexamethasone in combination with
metaclopramide during the 3 days following therapy. On the basis
of these results, and in view of XR11576’s development as an oral
therapy, the 150mgday
 1 dose level was not considered feasible
and the recommended dose of XR11576 for further studies is
120mgday
 1 administered on days 1–5 every 3 weeks.
Tolerability
Diarrhoea and fatigue were the principal DLTs and were observed
both at the 180 and 150mgday
 1 dose level. They also constituted
the most common nonhaematological effects of XR11576 together
with nausea and vomiting (Tables 2 and 3). Both the incidence and
severity of diarrhoea increased with the dose of XR11576
administered. The median day of onset was day 5 (range 1–15
days), with a median duration of 4 days (range, 1–14 days). In
most patients, the diarrhoea was self-limiting. Five patients
required treatment with loperamide. Patients treated at the lower
dose levels did not routinely receive antiemetic premedication with
their first dose. However, once established, nausea and vomiting
were difficult to treat. Therefore, it was decided to introduce
prophylactic treatment with 5HT3 antagonists at the 180mgday
 1
dose level. Since single-agent treatment with 5HT3 antagonists
could not prevent nausea or vomiting, it was decided to combine
the 5HT3 antagonists with dexamethasone for the additional
patients treated at the 120mg dose level. Although the treatment
with XR11576 was better tolerated, all patients experienced mild to
moderate nausea. Only one patient developed grade 1 alopecia
during treatment with XR11576.
Overall, the haematological toxicity was mild (Tables 2 and 3).
Only one patient, who was heavily pretreated, experienced grade 4
neutropenia, which was not complicated by fever. In the patient
who received 10 cycles, there was no evidence of cumulative
haematological toxicity. Thrombocytopenia was limited to grade 1
and 2, and only observed in three patients, two of whom were
treated at the highest dose level. In seven patients grade 1 anaemia
was encountered, in four patients grade 2 anaemia. Anaemia did
not seem to be dose related.
Electrocardiograms were performed prior to treatment and
following first drug administration. No significant abnormalities in
ECG tracings were observed. No clinical signs of impaired cardiac
function were observed in any of the patients treated.
No treatment-related deaths were reported.
Antitumour activity
No objective responses were observed. Four patients experienced
stabilisation of their disease (melanoma, cervical cancer and
parotid cancer) for a median duration of 12 weeks (range 12–30
weeks).
Pharmacokinetics
Full kinetic data were obtained on days 1 and 4 from 21 patients
following the administration of XR11576.
The plasma concentration–time profiles of XR11576 were
similar for all patients studied, with a representative example
shown in Figure 2. Maximum peak drug levels occurred
at 3.6970.79h post dose and declined with a mean terminal
half-life of up to 70h. Inspection of the scatterplots of dose vs
either AUC0–N (Figure 3A) or Cmax (Figure 3B) for XR11576
revealed an increase of both parameters with the dose level
administered.
Table 2 Toxicity in the first cycle according to NCI-CTC version 2.0
WBC ANC Plt Nausea Vomiting Fatigue Diarrhoea
Dose (mgday
 1) No. pts per cycle 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 1 2 3 4 1 2 3 4 1 2 3 4 DLT
30 3/13 – – – – – – – – – – – – 2 – – ––––11––– – – – –
60 4/10 – – – – – – – – – – – – 3 – – 2–––1–1–1 – – – –
120 8/16 1 – – – – – – – – – – – 5 3 – 122–33––1 2 1 – 1
1 8 0 3 / 5 – – – – – – 1 – 2 – – –3–––3––111–1 1 – – 1
1 5 0 3 / 5 – 1 – – – – – 1 1 – – –12––3–––3––1 1 1 – 1
No. pts¼number of patients; Plt¼platelets; DLT¼dose-limiting toxicity.
Table 3 Worse toxicity per cycle for all cycles according to NCI-CTC version 2.0
WBC ANC Plt Nausea Vomiting Diarrhoea Fatigue
Dose (mgday
 1) No. pts per cycle 1 2 3 4123412341 2 3 1 2 3 4 1 2 3 4 1234
30 3/13 – –––––––––––3 2 – 3– – – 1 – – – 12––
60 4/10 – –––––––––––6 – – 4– – – 1 – – – 222–
120 8/16 2 –––––––1–––8 7 – 3 5 2– 3 3 1 – 551–
1 8 0 3 / 5 ––––––1–2–––3 1 1 – 5– – 1 1 – 1 112–
150 3/5 – 1 – – – – – 1 1 – – – 2 2 – 1 3 – – 1 1 1 – – 4 – –
No. pts¼number of patients; Plt: platelets.
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Figure 2 Representative plasma concentration–time profile of
XR11576 in one patient treated at 120mgday
 1 on day 1 (open symbols)
and 4 (closed symbols) of the first cycle.
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lThe long half-life relative to the dosing interval resulted in
accumulation in plasma of XR11576, such that exposure was
approximately two-fold higher by the last day of dosing.
The intrapatient variability was assessed by comparing the
AUC0–24h values on days 1 and 4 during cycle 1 with the
corresponding values during cycle 2. In general, systemic exposure
during cycle 1 was not appreciably different from that observed
during cycle 2, with average AUC0–24h ratios ranging from 0.9 to
1.6. The interpatient variability in the observed PKs was large, with
coefficients of variation in AUC values as high as 4100%.
Over the dose levels studied, the systemic exposure to XR11576
increased with increasing dose. Overall, systemic exposure
increased in a greater than dose-proportional manner (Figure 3).
The mean PK parameters determined using a noncompartmental
analysis are listed in Table 4. In all patients, the PKs of XR11576
were also determined in the second cycle. There were no
significant differences between PK parameters derived from paired
Table 4 Summary of the pharmacokinetics of XR11576 during the first treatment course
Dose level (mgday
 1) N AUC0-t (nghml
 1) AUC0–N (nghml
 1) Cmax (ngml
 1) Tmax (h) T1/2(h) R0
30 3
Mean 36.2 50.0 8.07 2.5 5.53 1.56
cv% 83.0 88.2 53.8 34.6 75.4 17.9
60 4
Mean 178 517 21.7 3.50 68.8 1.87
cv% 98.3 26.3 60.5 16.5 70.4 30.2
120 8
Mean 329 535 41.1 3.75 31.2 1.93
cv% 109 94 90.4 27.6 162 78.6
180 3
Mean 970 1812 112 4.67 NC 1.34
cv% 45.7 27.6 63.4 24.7 NC 7.1
150 3
Mean 1708 2236 167 4.00 NC 1.53
cv% 9.89 7.78 40.9 0 NC 5.9
N¼number of patients; cv¼coefficient of variation; AUC¼area under the concentration–time curve; Cmax¼peak plasma level; Tmax¼time to maximal concentration;
T1/2¼terminal elimination half-life; R0¼ratio of accumulation; NC¼not calculated as terminal exponential phase could not be unambiguously identified.
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Figure 3 Relationship between AUC (A) and Cmax (B) on day 1 of the
first cycle of XR11576 as a function of dose administered per day.
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Figure 4 Relationship between the absolute apparent CL/F (calculated
by dividing the absolute administered oral dose of XR11576 by the AUC of
XR11576).
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ldata sets (data not shown), suggesting a time-independent PK
behaviour when XR11576 is administered on days 1–5 every 21
days. Less than 0.5% of the administered dose of XR11576 was
excreted unchanged in urine within 24h after drug administration.
To test the appropriateness of flat dosing strategy in this study, the
BSA was plotted vs the absolute apparent CL/F (calculated by
dividing the absolute administered oral dose of XR11576 by the
AUC of XR11576) in Figure 4. As expected, no relationship was
found between the apparent CL/F and BSA.
DISCUSSION
Dual topoisomerase I and II inhibition might have advantages over
either topoisomerase I or II inhibition since both cell cycle-
dependent and -independent topoisomerases are targeted. In
preclinical studies, this property resulted in enhanced antitumour
activity. The availability of an oral formulation of XR11576, a dual
topoisomerase inhibitor, for clinical use would enable a convenient
method of prolonged drug administration and provides the
opportunity for cost-effective outpatient therapy. In the present
study, XR11576 was administered orally on a daily-times 5 regimen
every 3 weeks. Dose-limiting toxicity consisted of diarrhoea and
fatigue. Diarrhoea is a well-known side effect of camptothecin and
its derivatives. Oral administration of irinotecan (Soepenberg et al,
2002), 20-S-camptothecin (Natelson et al, 1996), 9-nitrocamp-
tothecin (Verschraegen et al, 1998), topotecan (Creemers et al,
1997; Gerrits et al, 1998) and 9-AC (Mani et al, 1998; De Jonge et al,
1999) induced diarrhoea in 24–54% of administered cycles.
Prolonged oral administration (21 days) of topotecan resulted in
severe diarrhoea in 22%, which could not be controlled with
loperamide (Creemers et al, 1997). In our present study, diarrhoea
grade 1–2 was observed in 26% and grade 3–4 in 6% of the cycles.
In most patients diarrhoea was self-limiting, not requiring any
therapy.
Although nausea and vomiting were not considered as a DLT, all
patients at the recommended dose level of 120mgday
 1 experi-
enced nausea and/or vomiting grade 1–2, despite a vigorous
prophylactic antiemetic regimen. With the exception of the first
two dose levels, nausea and vomiting started within the first 2 days
of treatment and tended to have a more protracted course with
increasing dose (median duration 2 days (range 1–5) at 30mg to a
median duration of 6 days (range 1–20) at dose level 180mg).
Acknowledging that this is a major drawback for an oral
formulation, an alternative regimen employing day 1 and 8
administration every 21 days is being evaluated with the
assumption that such a regimen would require a more limited
use of antiemetics. If this schedule results in a higher dose
intensity and more manageable gastrointestinal side effects, it will
be considered for phase II testing.
Haematological toxicity was mild in this study and not clearly
dose- or exposure-related. This is in contrast to the haematological
toxicity observed with most topoisomerase I inhibitors. The
limited haematological toxicity might be related to the relatively
limited systemic exposure to the drug, although the AUC values
measured from the dose level of 120mg onwards were within the
range of AUC values associated with preclinical activity.
In the present study, the systemic exposure to XR11576 rose
more than proportional to increasing dose. Oral bioavailability
studies have not been performed because of lack of an intravenous
formulation of the drug. XR11576 was administered at fixed doses
during the study. Using linear regression analysis, XR11576 oral
clearance was not significantly related to patient body surface area,
confirming that the application of dosing per body surface area
would not have optimised dosing of this agent.
In this study, the DLTs of XR11576 were diarrhoea and fatigue.
The recommended dose for phase II studies of XR11576 is 120mg
administered orally, on days 1–5 every 21 days. Alternative
regimens are currently being explored.
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